ResMed Inc. vs TotalEnergies SE — how do they compare? ResMed Inc. trades at $225.92 (market cap $31.89B), while TotalEnergies SE trades at $86.62 (market cap $191.82B). The key difference: TotalEnergies SE is far larger — about 6× ResMed Inc.'s market cap, and TotalEnergies SE pays the higher dividend (4.93%). Which is the better fit depends on your goals — on Pluang, investors hold ResMed Inc. for 51 Days and TotalEnergies SE for 90 Days on average.
| RMD | TTE | |
|---|---|---|
Market Cap | $31.89B | $191.82B |
Volume | 618,314 | 3,311,339 |
Sector | Health | Energy |
52-Week High | $277.88 | $93.60 |
52-Week Low | $182.82 | $57.39 |
Typical Hold Time | 51 Days | 90 Days |
Enterprise Value | $31.24B | $222.81B |
Dividend Yield | 1.16% | 4.93% |
Signals from Pluang's Aura AI — not financial advice
ResMed (RMD) trades at $225.98, up 2.4% today, with a bullish technical signal and strong fundamentals. Revenue grew to $5.15B in 2025, with net income at $1.40B and a 26.94% net margin. Recent earnings beats and a 12-14% EPS growth outlook support momentum. The stock is near its pivot point of $227, with support at $225 and resistance at $228.
Outlook is positive with analyst consensus at Buy and a $242.70 price target. Risks include competitive pressures and ongoing legal investigations. Institutional buying and solid cash flow growth underpin the bullish case, though macroeconomic and regulatory factors warrant monitoring.
TotalEnergies (TTE) trades at $84.23, up 0.3% on the day, with a bearish technical signal from moving averages but neutral oscillators. The stock shows attractive valuation with a P/E of 10.54 and P/S of 0.94. Recent earnings beat expectations in Q1 and Q2 2026, though revenue has declined from 2022 peaks. The company maintains a strong cash flow profile and has announced a $10 billion investment in Argentina, alongside a commitment to grow dividends by 5% annually through 2030.
The outlook is supported by strategic expansions in LNG and power, but risks include volatile energy prices and execution of capital projects. Analyst consensus is bullish with a $95.33 price target, implying potential upside. Investors should weigh the company's solid fundamentals and shareholder returns against sector-specific headwinds and macroeconomic sensitivity.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →TotalEnergies is an integrated oil and gas company that explores for, produces, and refines oil around the world. In 2021, it produced 1.5 million barrels of liquids and 7.2 billion cubic feet of natural gas per day. At year-end 2020, reserves stood at 12.1 billion barrels of oil equivalent, 45% of which are liquids. During 2021, it had LNG sales of 42 Mt. The company owns interests in refineries with capacity of nearly 1.8 million barrels a day, primarily in Europe, distributes refined products in 65 countries, and manufactures commodity and specialty chemicals. It also holds a 19% interest in Russian oil company Novatek. At year-end, its gross installed renewable power generation capacity was 10.3 GW.
Read more on TTE →